In silico drug design lab of Chenglong Li, PhD, associate professor of Medicinal Chemistry and Biophysics in Ohio State’s College of Pharmacy (left). The STAT3 inhibitor being developed by OSUCCC - James and Ohio State collaborators was designed by Li and his lab. Here, he and graduate research associate Ryan Pavlovicz, examine a molecule designed using in silico methodology (i.e., by computer ).
Li in silico drug design lab. Pavlovicz and Li examine a computer model of a molecule designed by computation.
Li has a wet lab as well as a computer lab for drug-development research.
Guqin Shi, a graduate student in Medicinal Chemistry, works in Li's wet lab.
Organic synthesis lab. After the Li lab computationally designed version 1 of the STAT3 inhibitor, called FLLL-10, the agent was synthesized in the lab of medicinal chemist James Fuchs, PhD, in the College of Pharmacy. Here, Eric Schwartz, a graduate student in Fuchs' lab, is working to purify FLLL-10.
Fuchs Lab. Column chromatography is used to separate FLLL-10 from impurities. The agent, dissolved in a solvent, is caught in test tubes.
Fuchs Lab. Schultz collects pure FLLL-10 by concentrating it under reduced pressure.
Fuchs Lab. Schultz prepares a thin-layer chromatography gel to determine the purity of the FLLL-10 in the test tubes.
Fuchs Lab. The thin-layer chromatography gel under shortwave ultraviolet light (UV). Shortwave UV helps determine the purity of the FLLL-10 collected by column chromatography.
Fuchs Lab. The thin-layer chromatography gel under longwave UV. Certain compounds -- including FLL-10 itself -- show up better under longwave UV. This view also helps determine the purity of FLLL-10 following chromatography.
Fuchs Lab. The solvent will be cooked off, leaving FLLL-10 in the round-bottom flask at left.
Fuchs lab. The vial contains pure FLLL-10; the yellow powder is its more potent derivative, the second generation STAT3 inhibitor, FLLL-32.
Following the synthesis of the STAT3 inhibitor FLLL-10, graduate student Eric Schwartz (left) and principal investigator James Fuchs, PhD (center), hand off a sample to OSUCCC - James researcher and tumor immunologist Gregory Lesinski, PhD, MPH, for biological testing in cancer cells and animal models in his lab. Other OSUCCC - James labs also used the sample for testing against different cancer cell lines, including canine osteosarcoma by veterinarian Cheryl London, DVM, PhD, in the College of Veterinary Medicine.
The Lesinski lab is a biology lab. The investigators tested FLLL-32, a STAT3 inhibitor developed by OSUCCC - James researchers, in melanoma, renal-cell carcinoma and pancreatic cancer cell lines. Shown here are Jennifer Yang, a graduate research associate (front); Omar Elnaggar an undergraduate student and Zeenath Ameen an undergraduate student and Pelotonia fellow.
Leskinski lab. Zheng Che, an undergraduate student, uses gel electrophoresis to separate proteins from cancer cells treated with FLLL-32 to learn how the agent affected the cells.
Lesinski Lab. Electrophoresis separates proteins on a gel according to their size and electrical charge.
Lesinski lab. Principal investigator Gregory Lesinski, PhD, MPH (seated), and postdoctoral researcher Thomas Mace, PhD, examine a photomicrograph of cancer cells subjected to FLLL-32. The outcome of biological testing in cells and animal models determines whether a new agent is ready for clinical-trials testing in humans or requires more refining by Li's drug design lab and additional biological testing.